UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~November 2025

Commission File Number: 001-42526

Anbio Biotechnology

Wilhelm Gutbrod Str 21B, 60437,
Frankfurt am Main,
Germany
+49 16 0962 47281

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

OnChanges ~~February~~in ~~18, 2025, Anbio Biotechnology, a Cayman Islands exempted company (the “~~Company”)’s ~~entered~~Certifying ~~into an underwriting agreement with AC Sunshine Securities LLC~~Accountant., the representative of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters in a firm commitment underwritten initial public offering (the “IPO”) an aggregate of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the “Shares”), at offering price of $5.00 per share. The underwriting agreement is attached hereto as Exhibit 1.1 and is incorporated by reference herein.

~~The Company completed the IPO pursuant to its registration statement on Form F-1~~ (~~File No. 333-284106, “Form F-~~1”), ~~originally~~Previous ~~filed~~Independent ~~with~~Registered ~~the~~Public ~~U.S. Securities and Exchange~~Accounting Commission (the “SEC”) on December 31, 2024, as amended (the “Registration Statement”). The Registration Statement was declared effective by the SEC on February 18, 2025. The Shares were previously approved for listing on The Nasdaq Global Market and commenced trading under the ticker symbol “NNNN” on February 19, 2025. On February 20, 2025, the Company closed its IPO.Firm

In(i) ~~connection~~Effective ~~with the IPO, the Company issued a press release~~ on ~~February~~November 1810, 2025, ~~announcing~~Anbio ~~the~~Biotechnology ~~pricing of~~ (the ~~IPO~~“Company”) ~~and~~terminated aYCM ~~press~~CPA ~~release on February 20, 2025 announcing the closing of the IPO, respectively~~INC. ~~Copies of each press release are attached hereto~~ as ~~Exhibit~~the ~~99.1~~Company’s ~~and~~independent ~~Exhibit~~registered ~~99.2~~public ~~and are~~accounting ~~incorporated by reference herein~~firm.

~~This~~(ii) ~~report~~The ~~does~~reports ~~not~~of ~~constitute~~YCM anCPA ~~offer~~INC. toon ~~sell, or~~consolidated ~~the~~balance ~~solicitation~~sheets of anthe ~~offer~~Company tofor ~~buy~~the fiscal year ended December 31, ~~nor~~2024 ~~shall~~and ~~there~~2023 beand ~~any~~the ~~sale~~consolidated statements of ~~these~~comprehensive ~~securities~~income in(loss), ~~any~~consolidated ~~state~~statements orof ~~jurisdiction~~changes in ~~which~~equity, ~~such~~and ~~offer~~consolidated statements of cash flows for the fiscal years ended December 31, ~~solicitation~~ or2024, ~~sale~~2023 ~~would~~and be2022, ~~unlawful~~did ~~prior~~not tocontain ~~the~~an ~~registration~~adverse opinion or ~~qualification~~disclaimer ~~under~~of ~~the~~opinion ~~securities~~and ~~laws~~were ofnot ~~any~~qualified ~~such~~or ~~state~~modified as to uncertainty, audit scope or ~~jurisdiction~~accounting principles.

(iii)

The decision to change the independent registered public accounting firm was approved by the Board of Directors of the Company.

(iv)

During the Company’s most recent fiscal year ended December 31, 2024 and through November 10, 2025, the date of dismissal, (a) there were no disagreements with YCM CPA INC. on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of YCM CPA INC., would have caused it to make reference thereto in its reports on the financial statements for such year and (b) there were no “reportable events” as described in Item 304(a)(1)(v) of Regulation S-K.

(v)

The Company provided YCM CPA INC. with a copy of this Current Report and has requested that it furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter is attached as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K.

(2) New Independent Registered Public Accounting Firm

On November 10, 2025, the Board of Directors of the Company and the Audit Committee of the Company approved and ratified the appointment of HTL International, LLC as its new independent registered public accounting firm to audit the Company’s financial statements, effective November 10, 2025. During the two most recent fiscal years ended December 31, 2024 and 2023 and any subsequent interim periods through the date hereof prior to the engagement of HTL International, LLC, neither the Company, nor someone on its behalf, has consulted HTL International, LLC regarding:

(i)

either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and either a written report was provided to the Company or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

(ii)

any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described in paragraph 304(a)(1)(v) of Regulation S-K.

Exhibit Index

Exhibit No.		Description
16.1		Letter from YCM CPA INC. addressed to the U.S. Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Anbio Biotechnology
Date: February 21, 2025	By:	/s/ Michael Lau
Date: November 12, 2025	By:	/s/ Michael Lau
	Name:	Michael Lau
	Title:	Chief Executive Officer

EXHIBIT INDEX

Exhibit No.		Description
1.1		Underwriting Agreement dated February 18, 2025 between the Company and AC Sunshine Securities LLC.
99.1		Press Release on Pricing of the Company’s Initial Public Offering
99.2		Press Release on Closing of the Company’s Initial Public Offering

Filing Compare · Anbio Biotechnology